Spinelab raises CHF 4.7 million in Series C financing round

Spinelab is specialized in developing motion preserving stabilization systems for the spine. Its lead product named Elaspine has already proved its worth. “Spinelab has rigorously documented the clinical performance of its flagship product, the motion preservation system Elaspine, over the last three years. This new funds will allow Spinelab to initiate commercial activities in Europe and to complete the development of its second core product”, said Thomas Zehnder, President & CEO of Spinelab.

Gerard Moufflet, Chairman of Spinelab added: “With a strong database of over 100 documented clinical cases with Elaspine in Europe, Spinelab is poised to demonstrate the superior clinical benefits and to position Elaspine as a leading device in this field.”

The company based at the Technopark Winterthur has raised Swiss francs 20 million since its first venture round end of 2006. Investors are BioMedInvest, VI Partners and SHS.

About Spinelab
Spinelab’s core product Elaspine is a pedicle screw based posterior motion preservation system for thoracolumbar spine. The key element is an elastic polymer rod with a patented form-fit connection to a mono-axial pedicle screw head. The system makes use of the viscoelastic material properties of the polymer rod and acts similarly to a damper.